Acceleron investors dig their heels in on Merck takeover bidActivist investors are pushing back against Merck & Co’s recent $11.5 billion deal to acquire Acceleron Pharma, arguing Share XAcceleron investors dig their heels in on Merck takeover bidhttps://pharmaphorum.com/news/acceleron-investors-dig-their-heels-in-on-merck-takeover-bid/
Merck confirms $11.5bn Acceleron takeover dealAfter days of speculation, Merck & Co confirmed today that it has agreed to acquire Acceleron Pharma $1.5 Share XMerck confirms $11.5bn Acceleron takeover dealhttps://pharmaphorum.com/news/merck-confirms-11-5bn-acceleron-takeover-deal/
Rumour mill says Acceleron is speeding towards $11bn saleUS biopharma company Acceleron is the next company heading for a takeover by a big pharma group – Share XRumour mill says Acceleron is speeding towards $11bn salehttps://pharmaphorum.com/news/rumour-mill-says-acceleron-is-speeding-towards-11bn-sale/
EHA21: Study raises BMS’ hopes for Reblozyl in less severe diseaseBristol-Myers Squibb has taken another step towards achieving its blockbuster hopes for beta thalassaemia-associated anaemia therapy Reblozyl, after Share XEHA21: Study raises BMS’ hopes for Reblozyl in less severe diseasehttps://pharmaphorum.com/news/eha21-study-raises-bms-hopes-for-reblozyl-in-less-severe-patients/
CHMP backs BMS’ first-in-class anaemia drug ReblozylBristol-Myers Squibb has moved a step closer to EMA approval of Reblozyl, a therapy for anaemia that has Share XCHMP backs BMS’ first-in-class anaemia drug Reblozylhttps://pharmaphorum.com/news/chmp-backs-bms-first-in-class-anaemia-drug-reblozyl/
Celgene scores FDA okay for thalassaemia drug ReblozylThe FDA has approved Celgene and Acceleron’s Reblozyl, which is the first drug to be approved in the Share XCelgene scores FDA okay for thalassaemia drug Reblozylhttps://pharmaphorum.com/news/celgene-scores-fda-okay-for-thalassaemia-drug-reblozyl/
Acceleron axes clinical development of muscular dystrophy drugAcceleron has axed clinical development of its ACE-083 in the inherited muscle-wasting disease muscular dystrophy, after the drug Share XAcceleron axes clinical development of muscular dystrophy drughttps://pharmaphorum.com/news/acceleron-axes-clinical-development-of-muscular-dystrophy-drug/
